What Is Povorcitinib?
Povorcitinib is a drug currently under investigation in clinical trials for various conditions. It is administered orally as a tablet form. Research is exploring its potential to treat several conditions, including Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis, and various forms of urticaria and pruritis. There are currently 16 trials involving Povorcitinib, with a total enrollment of 4,737 participants. The first trial began on 2022-11-17, and studies are ongoing, with the latest trial projected to conclude on 2026-05-14. All studies are sponsored by Incyte Corporation.
Uses and Conditions Under Study
Povorcitinib is being studied for its potential to treat a range of conditions, primarily focusing on inflammatory and dermatological disorders. The conditions under investigation include:
- Hidradenitis Suppurativa (HS): This is a chronic inflammatory skin condition characterized by painful lumps and abscesses. Povorcitinib is being studied in 5 trials for its potential to manage HS.
- NonSegmental Vitiligo: This condition causes the skin to lose its pigment, resulting in white patches on various parts of the body. Povorcitinib is being investigated in 2 trials for its effects on vitiligo.
- Prurigo Nodularis: This skin disease is characterized by intensely itchy, firm bumps that can appear anywhere on the body. Povorcitinib is being explored in 2 trials for this condition.
- Itch-related skin conditions: Povorcitinib is also being investigated for pruritis (itchy skin), urticaria (hives), chronic idiopathic urticaria, and chronic spontaneous urticaria. These conditions are characterized by severe itching and skin rashes. A total of 4 trials are exploring Povorcitinib's effect on these conditions.
- Moderate to Severe Asthma: For this chronic respiratory condition, Povorcitinib is being studied in 1 trial to assess its potential role in managing symptoms.
- Angioedema: Another condition under investigation is Angioedema, which involves swelling beneath the skin, often around the eyes, lips, or throat. Povorcitinib is being studied in 1 trial for this condition.
Additionally, 5 trials involving Povorcitinib include healthy participants. These studies typically assess the drug's safety, how it is absorbed and eliminated by the body, and its potential interactions with other medications.
Dosing
Povorcitinib is administered orally, primarily in tablet form. Clinical trials are exploring various investigational doses, often referred to as 'Povorcitinib Dose A,' 'Povorcitinib Dose B,' 'Povorcitinib Dose C,' or 'Povorcitinib Dose 1,' 'Povorcitinib Dose 2,' and 'Povorcitinib Dose 3.' The specific dose and frequency of administration are determined by the protocol of each individual study.
Some studies are also investigating Povorcitinib in combination with other medications. For instance, one study explores Povorcitinib alongside levonorgestrel (LNG)/ethinyl estradiol (EE), which are components of some hormonal contraceptives. Other trials combine Povorcitinib with an inhaled corticosteroid-long-acting beta-agonist (ICS-LABA) regimen, particularly in studies for asthma.
Side Effects
In clinical trials, the most common side effects reported by patients taking Povorcitinib included acne, nasopharyngitis, and headache. Acne was observed in 9.8% of patients receiving Povorcitinib, a notable increase compared to 1.7% of those on placebo. Nasopharyngitis, often described as common cold symptoms, was reported by 9.8% of patients on Povorcitinib and 10.0% on placebo, indicating a similar rate between the groups. Headache occurred in 7.3% of patients taking Povorcitinib, compared to 6.7% on placebo.
Other side effects observed in patients taking Povorcitinib, compared to placebo, included:
- Urinary tract infection: 2.6% of patients on Povorcitinib experienced this, versus 1.7% on placebo.
- Chronic spontaneous urticaria (hives): 2.6% of patients on Povorcitinib reported new or worsening hives, compared to 0.0% on placebo.
- Hypercholesterolaemia (high cholesterol): 2.1% of patients on Povorcitinib developed high cholesterol, versus 0.0% on placebo.
- Fatigue: 2.1% of patients on Povorcitinib experienced fatigue, compared to 0.0% on placebo.
These side effects were observed in a single trial involving 193 patients in the Povorcitinib treatment arm.
Clinical Trial Results
Povorcitinib for Chronic Spontaneous Urticaria
A clinical trial (NCT05936567) evaluated the efficacy and safety of Povorcitinib in adults with chronic spontaneous urticaria. The study measured changes in the Urticaria Activity Score over 7 days (UAS7), a scale used to assess the severity of hives and itching.
At Week 12, patients receiving 75 mg of Povorcitinib once daily experienced an average reduction of 23.91 points in their UAS7 score from baseline. This was a greater improvement compared to patients receiving 45 mg (19.83 points reduction), 15 mg (17.25 points reduction), or placebo (17.90 points reduction).
The trial also assessed the percentage of participants who achieved controlled disease, defined as a UAS7 score of 6 or less, by Week 12. 62.9% of patients on 75 mg Povorcitinib achieved controlled disease, significantly higher than the 44.1% on 45 mg, 30.3% on 15 mg, and 29.4% on placebo.
For complete remission, defined as a UAS7 score of 0, 42.9% of patients taking 75 mg Povorcitinib achieved this by Week 12. This compared to 29.4% of patients on 45 mg, 24.2% on 15 mg, and 23.5% on placebo.
Regarding the speed of response, patients on 75 mg Povorcitinib achieved controlled disease (UAS7 ≤ 6) in a median of 20.0 days. This was faster than patients on 15 mg or 45 mg Povorcitinib, both of whom reached controlled disease in a median of 54.0 days. The median time to controlled disease for the placebo group was not available.
Currently Recruiting Trials
Clinical trials for Povorcitinib are actively seeking participants for several studies designed to understand its effects across various conditions. These trials are crucial for gathering more information about the drug's safety and how well it works.
One study, NCT07588139, is a Phase 1 trial focused on evaluating how Povorcitinib is absorbed and processed by the body. This study aims to understand the interstitial concentrations and plasma pharmacokinetics of multiple doses of oral Povorcitinib or topical Ruxolitinib cream in 24 healthy adult participants. It is designed for healthy individuals to help researchers understand the drug's basic behavior.
For adolescents living with moderate to severe hidradenitis suppurativa, a Phase 2 study, NCT07213973, is recruiting. This trial will evaluate the pharmacokinetics, safety, and efficacy of Povorcitinib over a 54-week open-label treatment period. The study plans to enroll 40 adolescent participants to assess the drug's impact on this challenging skin condition.
A large Phase 3 rollover study, NCT06855498, is also underway for participants who have previously been enrolled in other Incyte-sponsored clinical trials of Povorcitinib for hidradenitis suppurativa. This study aims to enroll 600 participants to continue monitoring the long-term effects and safety of Povorcitinib.
Finally, participants with inadequately controlled moderate to severe asthma may be eligible for a Phase 2 study, NCT05851443. This trial is designed to evaluate the effect of three different dosing regimens of Povorcitinib on pulmonary function, with an enrollment target of 240 participants.
Where to Participate
Clinical trials for Povorcitinib are accessible across a wide geographic area, with studies being conducted at 160 sites in 108 cities across 32 states. This broad reach aims to make participation convenient for a diverse group of individuals.
The top cities with the most recruiting sites include:
- Miami, Florida (8 sites)
- Tampa, Florida (5 sites)
- New York, New York (5 sites)
- Troy, Michigan (3 sites)
- Baltimore, Maryland (3 sites)
- Birmingham, Alabama (3 sites)
- Dallas, Texas (3 sites)
- Detroit, Michigan (3 sites)
- Phoenix, Arizona (3 sites)
- Hialeah, Florida (3 sites)
Eligibility for these trials generally includes participants between 12 to 65 years old, of all genders. Some studies specifically seek healthy volunteers, while others are open to children who meet the age criteria.
Development Timeline
The journey of Povorcitinib in clinical development began with its first trial in 2022, sponsored by Incyte Corporation. Since then, Incyte Corporation has been the sole sponsor, driving the research and development of this investigational drug. The latest planned trial is set to conclude in 2026, marking a continuous effort in its evaluation.
To date, a total of 16 clinical trials for Povorcitinib have been initiated, with a cumulative enrollment of 4,737 participants. These studies span various phases of development, including 5 in Phase 1, 3 in Phase 2, and 8 studies in Phase 3, indicating significant progression towards potential approval.
Povorcitinib's development pipeline has expanded considerably since its initial focus on conditions such as IBS-C and hyperphosphatemia. The research has broadened to explore its potential in a range of dermatological and inflammatory conditions, including NonSegmental Vitiligo, Prurigo Nodularis, Pruritis, Angioedema, Urticaria, Chronic Idiopathic Urticaria, and Chronic Spontaneous Urticaria (often referred to as Hives). More recently, its potential in Moderate to Severe Asthma has also entered clinical investigation, demonstrating a diverse and evolving therapeutic focus for Povorcitinib.